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Women infected with human immunodeficiency vi-
rus type 1 (HIV) receive antiretrovirals (ARVs) during 
pregnancy for prophylaxis (PR) [prevention of mother-
to-child transmission (MTCT) of HIV] or for the treat-
ment (TR) of their own HIV infection. Concerns have 
been raised regarding the discontinuation of ARVs after 
delivery (among women who received ARVs for PR) in 
light of the results of the studies of structured TR in-
terruption among HIV-infected individuals receiving 
ARVs for TR (Ananworanich et al. 2006, El-Sadr et al. 
2006, Ruiz et al. 2007). For example, in the SMART 
trial, HIV-infected subjects with CD4+ counts above 
350 cells/mm3 were randomly assigned to the continuous 
or episodic receipt of ARV therapy. The latter group only 
used ARVs when the CD4+ count decreased to below 
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250 cells/mm3 and had a significantly higher rate of op-
portunistic infections and all-cause mortality (El-Sadr 
et al. 2006). The results of studies evaluating changes in 
the plasma HIV RNA concentration [viral load (VL)], the 
CD4+ lymphocyte percentage (CD4%) or absolute CD4+ 
lymphocyte count, or the HIV clinical disease stage in 
the postpartum (PP) period among HIV-infected women 
continuing or discontinuing ARVs after pregnancy have 
shown conflicting results (Cao et al. 1997, Melvin et al. 
1997, Watts et al. 2003, Martin et al. 2006, Tungsiripat 
et al. 2007, Cavallo et al. 2010). To avoid the effect of 
a higher volume of distribution on absolute CD4+ lym-
phocyte counts, the CD4% should be used for monitor-
ing T lymphocytes during pregnancy and PP (Miotti et 
al. 1992, Ekouevi et al. 2007). We analyzed data from 
the Eunice Kennedy Shriver National Institute of Child 
Health and Human Development (NICHD) International 
Site Development Initiative (NISDI) Perinatal Study 
to determine factors associated with a VL increase or 
a CD4% decrease among HIV-infected women who re-
ceived ARVs during pregnancy, according to whether or 
not ARVs were discontinued after delivery. 
PATIENTS, MATERIALS AND METHODS
NISDI Perinatal Study - The NISDI Perinatal Study 
was a prospective cohort study of HIV-infected women 
and their children conducted at multiple sites in Latin 
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The goal of this study was to evaluate changes in plasma human immunodeficiency virus (HIV) RNA concentra-
tion [viral load (VL)] and CD4+ percentage (CD4%) during 6-12 weeks postpartum (PP) among HIV-infected women 
and to assess differences according to the reason for receipt of antiretrovirals (ARVs) during pregnancy [prophy-
laxis (PR) vs. treatment (TR)]. Data from a prospective cohort of HIV-infected pregnant women (National Institute 
of Child Health and Human Development International Site Development Initiative Perinatal Study) were analyzed. 
Women experiencing their first pregnancy who received ARVs for PR (started during pregnancy, stopped PP) or for 
TR (initiated prior to pregnancy and/or continued PP) were included and were followed PP. Increases in plasma VL 
(≥ 0.5 log
10
) and decreases in CD4% (≥ 20% relative decrease in CD4%) between hospital discharge (HD) and PP 
were assessed. Of the 1,229 women enrolled, 1,119 met the inclusion criteria (PR: 601; TR: 518). At enrollment, 87% 
were asymptomatic. The median CD4% values were: HD [34% (PR); 25% (TR)] and PP [29% (PR); 24% (TR)]. The 
VL increases were 60% (PR) and 19% (TR) (p < 0.0001). The CD4% decreases were 36% (PR) and 18% (TR) (p 
< 0.0001). Women receiving PR were more likely to exhibit an increase in VL [adjusted odds ratio (AOR) 7.7 (95% 
CI: 5.5-10.9) and a CD4% decrease (AOR 2.3; 95% CI: 1.6-3.2). Women receiving PR are more likely to have VL 
increases and CD4% decreases compared to those receiving TR. The clinical implications of these VL and CD4% 
changes remain to be explored. 
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America and in the Caribbean (Read et al. 2007). ARVs 
for HIV-infected women and children had to be available 
at each participating site, along with alternatives to breast-
feeding. The primary objectives of this observational 
study included assessing the use of ARVs for the preven-
tion of MTCT and for the woman’s own health. Enroll-
ment began in 2002 and was completed in 2007. Women 
were eligible for enrollment if their pregnancy was con-
firmed, their HIV infection documented, they intended to 
deliver at a participating clinical site and to be followed 
up (along with their children) after delivery or birth and 
they were willing and able to provide informed consent. 
Enrollment had to occur before delivery. Signed informed 
consent was obtained for all subjects before enrollment 
into the study. The protocol was approved by the ethical 
review board at each clinical site, as well as by institution-
al review boards at the sponsoring institution (NICHD) 
and at the data management center (Westat).
Maternal study visits were conducted during preg-
nancy, at delivery, at hospital discharge (HD) after de-
livery and at 6-12 weeks and six months PP. During 
each of these visits, a medical history was obtained, 
a physical examination was performed and laboratory 
samples were obtained (except at the delivery and the 
6-month PP visits). The virological, immunological and 
clinical characteristics of the women were assessed 
during pregnancy, at the time of HD after delivery and 
at the 6-12 week PP visit. Maternal clinical disease 
staging was performed at each visit using the US Cen-
ters for Disease Control and Prevention classification 
system (CDC 1992).
Study population and definitions for this analysis - 
The study population for this analysis was restricted to 
women enrolled in the NISDI Perinatal Study as of Oc-
tober 2007, with their first pregnancy during the study, 
who were followed until at least the 6-12 week PP visit, 
who received ARVs during pregnancy and for whom 
the reason for receipt ARVs was known. The receipt of 
ARVs during pregnancy was categorized as either PR 
or TR. Women were classified as having received PR if 
they were not receiving ARVs when they became preg-
nant, but they initiated one or more ARVs during preg-
nancy and discontinued these drugs at or before the 6-12 
week PP visit. Otherwise, women were classified as hav-
ing received TR if they were receiving ARVs when they 
became pregnant or continued ARVs after the 6-12 week 
PP visit. The outcome variables of interest were changes 
between the HD visit and the 6-12 week PP visit defined 
as: an increase in plasma VL (≥ 0.5 log10 increase) and 
a decline in CD4% (≥ 20% relative decrease). Other co-
variates were defined as follows: homemakers, unem-
ployed individuals and students were classified as not 
gainfully employed outside of the home and all others 
were classified as gainfully employed outside of the 
home. A maternal history of substance use during the 
index pregnancy was ascertained through maternal in-
terview at enrollment.
Data collected from a small part of the current cohort 
(4% of the study population) has been published else-
where (Cavallo et al. 2010).
Statistical analysis - The associations of categori-
cal variables with VL increase and CD4% decline at the 
6-12 week visit were evaluated using the Fisher-Free-
man-Halton exact test. Variables at least marginally as-
sociated with VL increase and CD4% decline (p ≤ 0.20) 
were considered candidates for multivariable logistic 
regression modelling. Both stepwise selection and back-
ward elimination strategies were applied to determine 
whether both selection procedures arrived at the same 
parsimonious model (using a 5% significance level).
Ethics - The ethical protocol was approved by the 
ethical review board at each clinical site, as well as by 
institutional review boards at the sponsoring institution 
(NICHD) and at the data management center (Westat).
RESULTS
Size and characteristics of the study population - As 
of October 2007, there were 1,229 women enrolled in the 
NISDI Perinatal Study. Of these, there were 1,174 first 
pregnancies in the study. Of the 1,174 pregnant women, 
three were lost to follow-up between enrollment and the 
6-12 week visit. Of the remaining 1,171 women, 1,163 
received one or more ARVs during pregnancy. The rea-
son for the receipt of ARVs during pregnancy could not 
be determined for 44 women. Thus, the study population 
comprised 1,119 women (601 received ARVs as PR and 
518 received ARVs as TR).
The characteristics of the study population of 1,119 
women, overall and according to the receipt of ARVs for 
PR or TR, are shown in Table I. Several characteristics 
varied significantly (p < 0.05) according to the receipt of 
PR vs. TR, including country of residence, age, educa-
tion and tobacco use during pregnancy.
At enrollment and at HD, a greater proportion of 
women in the PR group were asymptomatic or only 
mildly symptomatic (clinical stage A) than women in 
the TR group. Women in the PR group were more likely 
to have received 1-2 nucleoside reverse transcriptase in-
hibitors (NRTIs) as their most complex ARV regimen of 
≥ 28 days during pregnancy or to have received ARVs 
for < 28 days during pregnancy, than women in the TR 
group. Finally, at 6-12 weeks PP, women in the PR group 
were more likely to be at clinical stage A than women in 
the TR group (Table I).
A greater proportion of women in the PR group had a 
CD4% ≥ 29% at enrollment (63.6%) and at HD (74.2%). 
At 6-12 weeks PP, they were more likely to have a CD4% 
≥ 29% (52.7%) than women in the TR group. The per-
centage of women with VL < 1,000 copies/mL at en-
rollment and at HD was not different between the two 
groups. However, women in the TR group were more 
likely to have a VL < 1,000 copies/mL at 6-12 weeks PP 
(67.4%; p < 0.0001) (Table II).
The median CD4% at HD was 35% (range 6-67%) in 
the PR group and 26% (1-62%) in the TR group. At 6-12 
weeks PP, the median CD4% was 30% (3-69%) in the PR 
group and 25% (1-53%) in the TR group. The median VL 
at HD was 200 copies/mL for both groups. However, at 
6-12 weeks PP, the median VL was 200 copies/mL for the 
TR group, compared to 7,910 copies/mL for the PR group.
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TABLE I
Characteristics of the study population, overall and according to reason for receipt of antiretrovirals (ARV) during pregnancy
Prophylaxis
(n = 601)
n (%)
Treatment
(n = 518)
n (%)
Total
(n = 1,119)
n (%) p value
At enrollment
Country of residence
Argentina 145 (24.1) 192 (37.1) 337 (30.1) < 0.0001
Bahamas 27 (4.5) 14 (2.7) 41 (3.7) -
Brazil 379 (63.1) 261 (50.4) 640 (57.2) -
Jamaica 26 (4.3) 7 (1.4) 33 (3) -
Mexico 13 (2.2) 29 (5.6) 42 (3.8) -
Peru 11 (1.8) 15 (2.9) 26 (2.3) -
Age (years)
< 20 49 (8.2) 15 (2.9) 64 (5.7) < 0.0001
20-29 373 (62.1) 245 (47.3) 618 (55.2) -
≥ 29 179 (29.8) 258 (49.8) 437 (39) -
Education (years)
≥ 13 20 (3.3) 35 (6.8) 55 (4.9) 0.0008
7-12 363 (60.4) 340 (65.6) 703 (62.8) -
0-6 218 (36.3) 143 (27.6) 361 (32.3) - 
Crowding (number of persons living in the household)
1-3 260 (43.3) 245 (47.3) 505 (45.1) 0.18
≥ 4 341 (56.7) 273 (52.7) 614 (54.9) -
Gainfully employed outside the home
Yes 134 (22.3) 126 (24.3) 260 (23.2) 0.42
No 467 (77.7) 392 (75.7) 859 (76.8) -
Tobacco use during pregnancy
Yes 159 (26.5) 108 (20.8) 267 (23.9) 0.03
No 442 (73.5) 410 (79.2) 852 (76.1) -
Alcohol use during pregnancy
Yes 57 (9.5) 47 (9.1) 104 (9.3) 0.81
No 544 (90.5) 471 (90.9) 1,015 (90.7) -
Cocaine use during pregnancy
Yes 18 (3) 12 (2.3) 30 (2.7) 0.48
No 583 (97) 506 (97.7) 1,089 (97.3) -
Marijuana use during pregnancy
Yes 12 (2) 13 (2.5) 25 (2.2) 0.56
No 589 (98) 505 (97.5) 1,094 (97.8) -
Clinical disease stage
A 578 (96.2) 395 (76.2) 973 (87) < 0.0001
B 13 (2.2) 46 (8.9) 59 (5.3) -
C 10 (1.7) 77 (14.9) 87 (7.8) -
At hospital discharge following delivery
Clinical disease stage
A 576 (95.8) 392 (75.7) 968 (86.5) < 0.0001
B 14 (2.3) 48 (9.3) 62 (5.5) -
C 11 (1.8) 78 (15.1) 89 (8) -
Most complex ARV regimen of ≥ 28 days during pregnancy
2 NRTIs + 1 PI 324 (53.9) 259 (50) 583 (52.1) < 0.0001
2 NRTIs + 1 NRTI 138 (23) 215 (41.5) 353 (31.5) -
1-2 NRTIs 98 (16.3) 16 (3.1) 114 (10.2) -
ARVs < 28 days 36 (6) 16 (3.1) 52 (4.6) -
Other 5 (0.8) 12 (2.3) 17 (1.5) -
At 6-12 weeks postpartum
Clinical disease stage
A 575 (95.7) 389 (75.1) 964 (86.2) < 0.0001
B 15 (2.5) 50 (9.6) 65 (5.8) -
C 11 (1.8) 79 (15.2) 90 (8) -
NRTI: nucleoside reverse transcriptase inhibitor; PI: protease inhibitor.
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VL increase and CD4% decline - Univariate analyses 
assessing associations with an increase in VL between 
HD and the 6-12 week PP visit were performed. Several 
factors were marginally associated (p ≤ 0.20) with a VL 
increase and were included in logistic regression analy-
ses, including the receipt of ARVs for PR (p < 0.0001), 
the country of residence (p < 0.0001), age (years) (p = 
0.004), education (years) (p = 0.03) and alcohol (p = 0.12) 
and cocaine use (p = 0.08) during pregnancy. Other vari-
ables associated with a VL increase were CD4% (p < 
0.0001), VL (copies/mL) (p < 0.0001) and HIV clinical 
disease stage (p < 0.0001) before the 6-12 week PP visit. 
Specifically, those with lower CD4% (at enrollment and 
at HD) were less likely to have a VL increase. Those 
with higher VL values (at enrollment and at HD) were 
less likely to have a VL increase. Finally, those with a 
more advanced HIV clinical disease stage (at enroll-
ment and at HD) were less likely to have a VL increase. 
Multivariable modelling incorporating all of the above 
variables resulted in a final model including four vari-
ables (Table III): reason for the receipt of ARVs during 
pregnancy, the country of residence, VL at HD and clini-
cal disease stage at HD. The country of residence was 
retained in the model to control for site variability. Those 
who received ARV PR during pregnancy had an almost 
eight-fold increase in risk of a VL increase at 6-12 weeks 
TABLE II
Results of CD4% and viral load (VL) according to reason for receipt of antiretrovirals during pregnancy
Prophylaxis
(n = 601)
n (%)
Treatment
(n = 518)
n (%)
Total
(n = 1,119) p value
At enrollment
CD4%
< 14 14 (2.5) 78 (16.5) 92 (9) < 0.0001
14-28 187 (33.8) 255 (53.8) 442 (43) -
≥ 29 352 (63.6) 141 (29.8) 493 (48) -
Unknown 48 44 - -
VL (copies/mL)
< 1,000 357 (60.7) 292 (56.8) 649 (58.9) 0.35
1,000 ≤ 10,000 120 (20.4) 109 (21.2) 229 (20.8) -
≥ 10,000 111 (18.9) 113 (22) 224 (20.3) -
Unknown 13 4 - -
At hospital discharge following delivery
CD4%
< 14 7 (1.4) 57 (12.3) 64 (6.7) < 0.0001
14-28 122 (24.4) 231 (50) 353 (36.7) -
≥ 29 370 (74.2) 174 (37.7) 544 (56.6) -
Unknown 102 56 - -
VL (copies/mL)
< 1,000 450 (84.9) 400 (80.6) 850 (82.8) 0.10
1,000 ≤ 10,000 44 (8.3) 61 (12.3) 105 (10.2) -
≥ 10,000 36 (6.8) 35 (7.1) 71 (6.9) -
Unknown 71 22 - -
At 6-12 weeks postpartum
CD4%
< 14 19 (3.3) 55 (11.3) 74 (7) < 0.0001
14-28 253 (44) 260 (53.4) 513 (48.3) -
≥ 29 303 (52.7) 172 (35.3) 475 (44.7) -
Unknown 26 31 -
VL (copies/mL)
< 1,000 142 (24) 347 (67.4) 489 (44.2) < 0.0001
1,000 ≤ 10,000 181 (30.6) 74 (14.4) 255 (23.1) -
≥ 10,000 268 (45.4) 94 (18.2) 362 (32.7) -
Unknown 10 3 - -
CD4%: CD4+ lymphocyte percentage.
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PP compared to those who received ARVs for TR [ad-
justed odds ratio (AOR) = 7.7; 95% CI 5.5-10.9]. Women 
with VLs ≥ 1,000 copies/mL at HD were significantly 
less likely to experience a VL increase at 6-12 weeks 
compared to those with VL < 1,000 copies/mL. Finally, 
women with more advanced clinical HIV disease at HD 
were significantly less likely to have a VL increase that 
those who were asymptomatic (Table III).
Univariate analyses assessing associations with 
CD4% decline between HD and the 6-12 week PP visit 
also were performed. Variables marginally associated (p 
≤ 0.20) with a CD4% decline that were incorporated into 
logistic regression analyses included crowding (number 
of persons living in the household) (p = 0.11), alcohol (p 
= 0.12) and marijuana (p = 0.12) use during pregnancy 
and the receipt of ARVs during pregnancy for PR (p < 
0.0001). Those with CD4% < 14% at enrollment (p = 
0.04) and at HD (p < 0.0001) were less likely to have 
a CD4% decline. Similarly, those with more advanced 
HIV clinical disease at enrollment (p = 0.0046) and at 
HD (p = 0.0049) were less likely to have a CD4% de-
cline. Multivariable modelling incorporating all of the 
above variables resulted in a final model including rea-
son for the receipt of ARVs during pregnancy, country 
of residence and CD4% at HD (Table IV). As before, 
country of residence was retained in the model to control 
for site variability. Those who received ARV PR during 
pregnancy had a higher risk of a CD4% decline at 6-12 
weeks PP compared to those who received ARVs for TR 
(AOR = 2.3; 95% CI 1.6-3.2). Those with a CD4% of 14-
28% at HD were less likely to have a CD4% decline at 
6-12 weeks PP compared to those with a CD4% ≥ 29% 
[AOR = 0.60 (95% CI 0.4-0.8)] (Table IV).
DISCUSSION
In this study of a relatively healthy population of HIV-
infected women [at enrollment, approximately half had a 
CD4% ≥ 29%, almost 60% had a VL below 1,000 copies/
mL and approximately 87% were asymptomatic (clinical 
stage A)], there was little clinical progression over time 
(by 6-12 weeks PP, 86% of women remained at clinical 
stage A). Although there were changes in CD4% and VL 
values over time (60% of women who received ARVs dur-
ing pregnancy for PR had a VL increase and 40% had a 
CD4% decline during the first few weeks PP vs. 19% and 
18%, respectively, of women who received ARVs during 
pregnancy for TR), most women who received ARVs for 
PR maintained a CD4% ≥ 29% (74% at HD and 53% at 
6-12 weeks PP). Eighty-five percent of women who re-
ceived ARVs for PR during pregnancy had a VL < 1,000 
copies/mL at HD. However, only 24% of these women 
had a VL < 1,000 copies/mL at 6-12 weeks PP.
The interruption of ARV PR after delivery is not 
completely analogous to structured ARV interruption 
(Ananworanich et al. 2006, Danel et al. 2006, El-Sadr 
et al. 2006, Pai et al. 2006, Ruiz et al. 2007). With the 
use of ARVs for the prevention of the MTCT of HIV, as-
suming the woman does not meet criteria for ARV TR, 
maternal ARVs are discontinued after the delivery of the 
infant. With the interruption of ARV TR, structured ac-
cording to VL and CD4+ count results, patients whose 
immunological status suggests a low risk of disease pro-
gression either continued therapy or interrupted it until 
the CD4+ count reached a certain threshold. Studies gen-
erally have demonstrated worse outcomes for those with 
structured TR interruptions.
TABLE III
Risk of viral load (VL) increase [unadjusted (OR) and adjusted odds ratios (AOR)]
VL increase
(n = 406)
n (%)
No VL increase
(n = 609)
n (%) p valuea OR 95% CI AOR 95% CI
Reason for receipt of 
antiretrovirals during pregnancy
Prophylaxis 313 (60) 209 (40) < 0.0001 6.4 4.8-8.6 7.7 5.5-10.9
Treatment 93 (18.9) 400 (81.1) - 1 - - -
Country of residence 
(at enrollment)
Argentina 149 (46.3) 173 (53.7) < 0.0001 1.4 1.1-1.9 2.1 1.5-3.1
Bahamas 18 (56.2) 14 (43.8) - 2.2 1.1-4.6 2.4 0.9-6.0
Brazil 212 (37.2) 358 (62.8) - 1 - 1 -
Jamaica 16 (61.5) 10 (38.5) - 2.7 1.2-6.1 1.6 0.6-4.4
Mexico 8 (20) 32 (80) - 0.4 0.2-0.9 1.3 0.5-3.3
Peru 3 (12) 22 (88) - 0.2 0.1-0.8 0.3 0.1-1.1
VL (copies/mL) at hospital 
discharge
< 1,000 400 (47.6) 441 (52.4) < 0.0001 1 - 1 -
≥ 1,000 6 (3.4) 168 (96.6) - 0.04 0.02-0.09 0.03 0.01-0.08
Clinical disease stage at hospital 
discharge
A 384 (44.1) 487 (55.9) < 0.0001 1 - 1 -
B 15 (24.2) 47 (75.8) - 0.4 0.2-0.7 0.9 0.4-1.7
C 7 (8.5) 75 (91.5) - 0.1 0.05-0.3 0.3 0.1-0.7
a: p value for unadjusted OR using Fisher-Freeman-Halton exact test for assessment of association of each characteristic with the 
outcome; CI: confidence interval.
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TABLE IV
Risk of CD4+ lymphocyte percentage (CD4%) decline [unadjusted (OR) and adjusted odds ratios (AOR)]
CD4% decline 
(n = 256)
n (%)
CD4% decline
(n = 692)
n (%) p valuea OR 95% CI AOR 95% CI
Reason for receipt of  
antiretrovirals during pregnancy
Prophylaxis 176 (35.7) 317 (64.3) < 0.0001 2.6 1.9-3.5 2.3 1.6-3.2
Treatment 80 (17.6) 375 (82.4) - - 1 1 -
Country of residence Argentina 89 (28.4) 224 (71.6) 0.60 1.0 0.8-1.4 1.2 0.9-1.7
Bahamas 11 (28.2) 28 (71.8) - 1.0 0.5-2.2 1.0 0.5-2.0
Brazil 139 (27.4) 369 (72.6) - - 1 1 -
Jamaica 3 (12.5) 21 (87.5) - 0.4 0.1-1.3 0.3 0.1-1.1
Mexico 9 (23.1) 30 (76.9) - 0.8 0.4-1.7 1.1 0.5-2.6
Peru 5 (20) 20 (80) - 0.7 0.2-1.8 0.8 0.3-2.3
CD4% at hospital discharge < 14 10 (15.6) 54 (84.4) < 0.0001 0.4 0.2-0.7 0.6 0.3-1.2
14-28 67 (19.3) 280 (80.7) - 0.5 0.4-0.7 0.6 0.4-0.8
≥ 29 179 (33.3) 358 (66.7) - - 1 1 -
a: p value for unadjusted OR using Fisher-Freeman-Halton exact test for assessment of association of each characteristic with the 
outcome; CI: confidence interval.
Previous studies have evaluated changes in the abso-
lute CD4+ count (Read et al. 2007) or percentage (Watts 
et al. 2003) among HIV-infected women who did or did 
not discontinue ARVs after delivery. As noted previous-
ly, the CD4% should be used to monitor T lymphocytes 
during pregnancy and PP (Miotti et al. 1992, Ekouevi 
et al. 2007). In a secondary analysis of the PACTG 185 
clinical trial database (Watts et al. 2003), women who 
continued ARV therapy after delivery were compared 
to those who discontinued therapy. All enrolled wom-
en had CD4+ lymphocyte counts below 500 cells/mm3 
at enrollment. Most (86%) received zidovudine (ZDV) 
alone, while 14% received two NRTIs during pregnan-
cy. Changes in CD4+ percentages between delivery and 
18 months PP did not differ significantly according to 
whether ZDV monotherapy was continued or discontin-
ued following delivery.
Similarly, other studies have assessed VL changes 
among HIV-infected women according to the continua-
tion or discontinuation of ARVs after delivery (Cao et al. 
1997, Melvin et al. 1997, Watts et al. 2003, Martin et al. 
2006, Tungsiripat et al. 2007). Some studies have sug-
gested no change in VL PP, although others indicated VL 
increases. First, in a retrospective study of HIV-infected 
women who discontinued ARVs at delivery (Tungsiripat 
et al. 2007), median VLs at 12-96 weeks PP were similar 
to values obtained during pregnancy. In another study 
of 44 HIV-infected pregnant women, 23 women initi-
ated ZDV therapy during pregnancy, 17 women did not 
use ARVs and four women used ZDV before and during 
pregnancy (Melvin et al. 1997). Overall, VLs remained 
stable until six weeks PP, but there was a trend toward an 
increase in VL values PP among those women who re-
ceived ZDV therapy only during pregnancy. However, in 
the Ariel Project (Cao et al. 1997), in which most women 
(85%) used ZDV during pregnancy for the prevention of 
MTCT and only a minority of women received it before 
pregnancy and continued after delivery (TR), a signifi-
cant VL increase was noted at two and six months PP. 
Among women enrolled in the PACTG 185 clinical trial 
(Watts et al. 2003), increases in VLs from delivery to 12 
weeks PP were observed, but VL changes were similar 
among women continuing or discontinuing therapy af-
ter delivery. In a study of HIV-infected pregnant women 
who received ZDV alone, combination ARV therapy and 
combination ARV PR (Martin et al. 2006), follow-up 
continued for an average of 33 months after delivery. At 
the end of follow-up, the median VL was higher in the 
ARV PR group (3.5 log copies/mL) compared to the TR 
group (1.7 log copies/mL). However, at the last follow-
up, the proportion of women on combination ARV ther-
apy with VLs < 50 copies/mL did not differ significantly 
according to whether ARV TR or PR was used during 
pregnancy (78% and 79%, respectively).
Finally, in a recent study comprising 112 HIV-infect-
ed pregnant women treated with potent ARVs (60 taking 
ARV for PR and 52 for TR), VL rebound affected women 
much more often in the PR than in the TR group (84.7% 
vs. 15.3%; p < 0.001) six months after delivery and was 
associated with ARV discontinuation. In addition, there 
was a higher decline in CD4 cell percentage among wom-
en in the PR group at this time (Cavallo et al. 2010).
We believe that these apparently conflicting results 
in the literature regarding the interruption of ARVs af-
ter delivery and VL rebound and/or CD4% decline may 
be related to the increased activity of the current ARV 
combinations against HIV, which are predominantly tri-
ple regimens, offered to most of our pregnant women, in 
comparison to mono or dual therapy, which were used 
by women in older studies and were not as efficient at 
reducing VL and improving CD4 count.
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PP increases in VLs have been attributed to physi-
ological changes occurring during pregnancy, such as 
blood volume expansion and elevated levels of estrogen 
and progesterone, that do not persist after delivery. How-
ever, in our study, we did observe a difference in VLs PP 
according to whether ARVs were continued or discon-
tinued following delivery (60% of women who received 
ARVs during pregnancy for PR had a VL increase).
The clinical implications of a VL increase in the PP 
period could be an increased risk of the development of 
viral resistance, possibly related to decreased adherence 
to ARVs in the PP period (Bardeguez et al. 2008). A re-
cent analysis of data from the NISDI Perinatal Study in-
cluded a predominantly asymptomatic population of HIV-
infected pregnant women who were diagnosed with HIV 
infection during pregnancy and, therefore, only initiated 
ARVs during the index pregnancy (Duran et al. 2007). In 
this analysis, 14% of women had ARV resistance muta-
tions at 6-12 weeks PP. The occurrence of resistance mu-
tations was not associated with clinical, immunological or 
virological disease stage at the time points of comparison 
(enrollment and 6-12 weeks PP), nor with the most com-
plex ARV regimens received during pregnancy. No sig-
nificant association was found between VL and resistance 
mutations in this population of pregnant women.
A major strength of this study is the large size of the 
cohort, with enrollment at multiple sites. Also, enroll-
ment occurred at clinical sites in six Latin American and 
Caribbean countries and the “country of residence” vari-
able was retained in the multivariable model to account 
for heterogeneity attributable to differences in the study 
populations and practices. The period of PP follow-up was 
relatively short, which prevented the analysis of HIV dis-
ease progression after 6-12 weeks PP. Adherence to ARVs 
was not assessed as part of the protocol. However, the pro-
tocol has been modified to incorporate a longer follow-up 
PP (up to 5 years) and assessments of adherence.
The clinical implications of the observed VL and 
CD4% changes remain to be explored. However, it is 
important to emphasize that clinical disease stage re-
mained quite stable throughout the duration of follow-
up. Similarly, most women in the PR group maintained 
a CD4% ≥ 29% throughout the duration of follow-up. 
Whether the observed early increase in VL among those 
who used ARVs for the prevention of MTCT affects the 
risk of developing ARV-resistant viral mutations is an 
important question to assess, particularly in terms of the 
response to future ARV TR regimens.
APPENDIx
NICHD International Site Development Initiative: Peri-
natal/LILAC and Pediatric/Places Protocols - Principal in-
vestigators, co-principal investigators, study coordinators, 
coordinating center representatives, and NICHD staff include: 
Argentina: Buenos Aires: Marcelo H. Losso, Irene Foradori, 
Claudia Checa, Silvina Ivalo (Hospital General de Agudos 
José María Ramos Mejía); Brazil: Belo Horizonte: Jorge Pinto, 
Victor Melo, Fabiana Kakehasi (Universidade Federal de Mi-
nas Gerais); Caxias do Sul: Ricardo da Silva de Souza, Nicole 
Golin, Sílvia Mariani Costamilan (Universidade de Caxias do 
Sul/ Serviço Municipal de Infectologia); Nova Iguaçu: Jose Pi-
lotto, Beatriz Grinsztejn, Valdilea Veloso, Gisely Falco (Hos-
pital Geral Nova de Iguacu - HIV Family Care Clinic); Porto 
Alegre: Ricardo da Silva de Souza, Breno Riegel Santos, Rita 
de Cassia Alves Lira (Universidade de Caxias do Sul/Hospital 
Conceição); Ricardo da Silva de Souza, Mario Ferreira Peix-
oto, Elizabete Teles (Universidade de Caxias do Sul/Hospital 
Fêmina); Regis Kreitchmann, Luis Carlos Ribeiro, Fabrizio 
Motta, Debora Fernandes Coelho (Irmandade da Santa Casa 
de Misericordia de Porto Alegre); Ribeirão Preto: Marisa M. 
Mussi-Pinhata, Geraldo Duarte, Adriana A. Tiraboschi Bár-
baro, Conrado Milani Coutinho, Anderson Sanches de Melo 
(Hospital das Clínicas da Faculdade de Medicina de Ribeirão 
Preto da Universidade de São Paulo); Rio de Janeiro: Ricardo 
Hugo S. Oliveira, Elizabeth S. Machado, Maria C. Chermont 
Sapia (Instituto de Puericultura e Pediatria Martagão Gestei-
ra); Esau Custodio Joao, Leon Claude Sidi, Ezequias Martins, 
Plinio Tostes Berardo (Hospital dos Servidores do Estado); São 
Paulo: Regina Celia de Menezes Succi, Prescilla Chow (Uni-
versidade Federal de São Paulo); Peru: Lima: Jorge Alarcón 
Villaverde (Instituto de Medicina Tropical “Daniel Alcides 
Carrión”- Sección de Epidemiología, UNMSM), Carlos Ve-
lásquez Vásquez (Instituto Nacional Materno Perinatal), César 
Gutiérrez Villafuerte (Instituto de Medicina Tropical “Daniel 
Alcides Carrión”- Sección de Epidemiología, UNMSM); Data 
Management and Statistical Center: Yolanda Bertucci, Lau-
ra Freimanis Hance, René Gonin, D. Robert Harris, Roslyn 
Hennessey, James Korelitz, Margot Krauss, Sharon Sothern 
de Sanchez, Sonia K. Stoszek (Westat, Rockville, MD, USA); 
NICHD: Rohan Hazra, Lynne Mofenson, Jennifer S. Read, 
Heather Watts, Carol Worrell (Eunice Kennedy Shriver Na-
tional Institute of Child Health and Human Development, 
Bethesda, Maryland, USA).
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